Evidence map›Paper›PMID 38098864›Full record

ArticleFrontiers in endocrinology2023

PPARG dysregulation as a potential molecular target in adrenal Cushing's syndrome.

Sharmilee Vetrivel, Mariangela Tamburello, Andrea Oßwald, Ru Zhang, Ali Khan, Sara Jung, Jessica E Baker, William E Rainey, Elisabeth Nowak, Barbara Altieri and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 4 countries.

Sharmilee VetrivelDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Mariangela TamburelloDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany.
Andrea OßwaldDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Ru ZhangDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Ali KhanDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany.
Sara JungDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Jessica E BakerDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, United States.
William E RaineyDepartment of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, United States.
Elisabeth NowakDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Barbara AltieriDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany.
Mario DetomasDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany.
Deepika WattsInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden (TUD)/Universitätsklinikum Carl Gustav Carus Dresden (UKD), Dresden, Germany.
Tracy Ann WilliamsDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Ben WielockxInstitute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden (TUD)/Universitätsklinikum Carl Gustav Carus Dresden (UKD), Dresden, Germany.
Felix BeuschleinDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Martin ReinckeDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Silviu SbieraDivision of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany.
Anna RiesterDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Ludwig-Maximilians-Universität München · DELMU Klinikum · DEUniversity of Würzburg · DETU Dresden · DEUniversity of Michigan–Ann Arbor · USUniversitätsklinikum Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We performed a transcriptomic analysis of adrenal signaling pathways in various forms of endogenous Cushing's syndrome (CS) to define areas of dysregulated and druggable targets. Methodology: Next-generation sequencing was performed on adrenal samples of patients with primary bilateral macronodular adrenal hyperplasia (PBMAH, n=10) and control adrenal samples (n=8). The validation groups included cortisol-producing adenoma (CPA, n=9) and samples from patients undergoing bilateral adrenalectomy for Cushing's disease (BADX-CD, n=8). Results: Pathway mapping based on significant expression patterns identified PPARG (peroxisome proliferator-activated receptor gamma) pathway as the top hit. Quantitative PCR (QPCR) confirmed that Outcome: This therapeutic effect was independent of the actions of ACTH, postulating a promising application of

Indexed as

Cushing SyndromeAdrenalectomyHumansHydrocortisoneHyperplasiaPPAR gammaHydrocortisonePPAR gammaPPARG protein, humanadrenocortical cell linecortisolhypercortisolismprimary bilateral macronodular hyperosiglitazonesteroidometranscriptome

Identifiers

PMID38098864
PMCPMC10720662
OpenAlexW4389226273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.